1. Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer.
- Author
-
Jin, Wu-mei, Zhu, Yan, Cai, Zhi-qiang, He, Na, Yu, Zhi-qiong, Li, Shuang, and Yang, Ji-yuan
- Subjects
- *
STOMACH cancer , *CLINICAL trials , *TIGHT junctions , *EPITHELIAL cells , *CANCER treatment , *GASTROINTESTINAL tumors - Abstract
Claudin18.2 is a tight junction protein, highly selective, generally expressed only in normal gastric mucosal epithelial cells, which can effectively maintain the polarity of epithelial and endothelial cells, thus effectively regulating the permeability and conductance of the paracellular pathway. Abnormal expression of Claudin18.2 can occur in various primary malignant tumors, especially gastrointestinal tumors, and even in metastatic foci. It regulates its expression by activating the aPKC/MAPK/AP-1 pathway, and therefore, the Claudin18.2 protein is a pan-cancer target expressed in primary and metastatic lesions in human cancer types. Zolbetuximab (IMAB362), an antibody specific for Claudin18.2, has been successfully tested in a phase III clinical trial, and the results of the study showed that combining Zolbetuximab with chemotherapy notably extends patients' survival and is expected to be a potential first-line treatment for patients with Claudin18.2(+)/HER-2(−) gastric cancer. Here, we systematically describe the biological properties and oncogenic effects of Claudin18.2, centering on its clinical-pathological aspects and the progress of drug studies in gastric cancer, which can help to further explore its clinical value. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF